SCHEMBL16420693

SCHEMBL16420693

Brc1ccccc1-c1cncc(-c2nnc(-c3ccccc3)o2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 8/20 0.63
RAB9A P51151 10/20 0.56
NPC1 O15118 9/20 0.56
TP53 P04637 4/20 0.56
GAA P10253 2/20 0.56
SMN1; SMN2 Q16637 7/20 0.54
ALDH1A1 P00352 4/20 0.54
TSHR P16473 3/20 0.54
HPGD P15428 3/20 0.54
MAPT P10636 2/20 0.54
ATAD2 Q6PL18 1/20 0.46
PIM1 P11309 1/20 0.45
PIM3 Q86V86 1/20 0.45
KDM4E B2RXH2 2/20 0.44
POLB P06746 1/20 0.44
NFKB1 P19838 1/20 0.43
MAPK1 P28482 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16420584 0.87 ATR (0.60) ATRRAB9ANPC1GAASMN1; SMN2
SCHEMBL16420547 0.83 NPC1 (0.61) ATRRAB9ANPC1TP53SMN1; SMN2
SCHEMBL16420541 0.83 ATR (0.63) ATRRAB9ANPC1GAASMN1; SMN2
SCHEMBL16420549 0.83 RAB9A (0.65) ATRRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL16420540 0.83 ATR (0.66) ATRRAB9ANPC1GAASMN1; SMN2
SCHEMBL16420548 0.81 ATR (0.65) ATRRAB9ANPC1GAASMN1; SMN2
SCHEMBL1840903 0.80 RAB9A (0.80) ATRRAB9ANPC1TP53GAA
SCHEMBL16420534 0.80 ATR (0.65) ATRRAB9ANPC1TP53SMN1; SMN2
SCHEMBL16420670 0.80 ATR (0.65) ATRRAB9ANPC1GAASMN1; SMN2
SCHEMBL16420650 0.80 RAB9A (0.68) ATRRAB9ANPC1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180170922-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2018-06-21 US disclosed
US-9701674-B2 Substituted pyrazines as ATR kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-07-11 US disclosed
US-20160311809-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-10-27 US disclosed
US-9365557-B2 Substituted pyrazin-2-amines as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-06-14 US disclosed
US-20150051187-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2015-02-19 US disclosed
US-20150031661-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031661-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 ATR 1/4885RAB9A 3002/4885NPC1 4192/4885
US-20180170922-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 ATR 1/4885RAB9A 3002/4885NPC1 4192/4885
US-20160311809-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 ATR 1/4885RAB9A 3002/4885NPC1 4192/4885
US-20150051187-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 ATR 1/4885RAB9A 3002/4885NPC1 4192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.